Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases, revealing that the Committee for Medicinal Products for Human Use…
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK plc (LSE/NYSE: GSK) has announced that the Committee for Medicinal…
NICE Recommends FILSPARI® (sparsentan) for Routine Use in the NHS to Treat Adults with IgA Nephropathy, Marking a Significant Step Forward in Rare Kidney Disease Management CSL Vifor has announced a major regulatory and reimbursement milestone for its innovative kidney…
Rethinking Nicotine: CVS Health Survey Uncovers Widespread Misconceptions About E-Cigarette Safety Among Young Adults Over the past few decades, the public conversation around tobacco and nicotine use has transformed dramatically. Once glamorized in movies, magazines, and advertisements, cigarette smoking has…
Trodelvy Marks Breakthrough in First-Line mTNBC Treatment with Positive Phase 3 ASCENT-03 Results Gilead Sciences has announced encouraging topline results from its Phase 3 ASCENT-03 clinical trial evaluating Trodelvy® (sacituzumab govitecan-hziy) in a particularly challenging patient population: individuals newly diagnosed…
GSK’s Nucala (Mepolizumab) Receives US FDA Approval as Add-On Maintenance Treatment for Adults with Eosinophilic Phenotype COPD GSK has officially announced a significant milestone in the treatment of chronic obstructive pulmonary disease (COPD) with the recent approval of Nucala (mepolizumab)…
Regeneron’s Linvoseltamab Combinations Show Strong Early Signals in Relapsed/Refractory Multiple Myeloma in Phase 1b Trial Regeneron Pharmaceuticals,has reported encouraging early findings from the ongoing Phase 1b LINKER-MM2 study, evaluating linvoseltamab in combination with either carfilzomib or bortezomib in patients with…
XTANDI Delivers Sustained Five-Year Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer: Landmark Findings from ARCHES and ENZAMET Trials Presented at ASCO 2025 Astellas Pharma Inc. and Pfizer Inc. have announced compelling new data from the long-term extension of the Phase…
FDA Approves Roche’s Susvimo as the First and Only Continuous-Delivery Treatment for Diabetic Retinopathy, Offering Nine-Month Dosing Durability In a significant advancement for patients suffering from diabetic retinopathy (DR), the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab…
A Call for Change: Ensuring Access and Insurance Coverage for People Living with Obesity In recent months, abrupt changes to insurance coverage for obesity management medications have placed thousands of Americans living with obesity in an impossible situation. Many now…
Merck Unveils Positive Phase 2 Results for Enpatoran, Showing Significant Reduction in Disease Activity in Patients with Cutaneous and Systemic Lupus with Active Rash Merck, a global leader in science and technology, has announced compelling new clinical data from its…
Roche’s Genentech Faces Setback as FDA Advisory Committee Rejects Columvi Expansion Proposal The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) delivered a significant blow to Genentech, a subsidiary of Roche, by voting overwhelmingly against the company’s…